Key facts
- This page summarizes Jan Hauser's Form 4 filing for Enfusion, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Apr 2025, 17:08.
Jan Hauser - 21 Apr 2025 Form 4 Insider Report for Enfusion, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 21 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2025, 17:08:05 UTC
- Prior SEC filing
- 31 Jan 2025
- Next SEC filing
- 16 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Campobasso, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jan Hauser filed Form 4 for Enfusion, Inc. on 21 Apr 2025.
Change
- Previous filing in this sequence was filed on 31 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENFN
transaction
Class A Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -57,925
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 21 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jan Hauser is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Disposed of pursuant to the Agreement and Plan of Merger, dated as of January 10, 2025 (the "Merger Agreement"), by and among Clearwater Analytics Holdings, Inc. (the "Parent"), Poseidon Acquirer, Inc., a direct, wholly-owned subsidiary of the Parent, Poseidon Merger Sub I, Inc., a wholly-owned subsidiary of the Parent, Poseidon Merger Sub II, LLC, an indirect subsidiary of the Parent, Enfusion, Inc. ("Enfusion"), and Enfusion Ltd. LLC, a subsidiary of Enfusion.
Footnote F2
Under the terms of the Merger Agreement, each eligible share of Enfusion's Class A common stock, par value $0.001 per share (the "Common Stock"), issued and outstanding was converted into the right to receive, at the election of the holder of such share of Common Stock, and subject to proration in accordance with the Merger Agreement: (i) cash in an amount equal to $5.85 and (ii) a number of shares of Class A common stock of the Parent, par value $0.001 per share (the "Parent Common Stock") equal to the Per Share Parent Stock Amount (as defined in the Merger Agreement) (the "Per Share Mixed Consideration"); (ii) a number of shares of Parent Common Stock equal to the Exchange Ratio (the "Per Share Stock Consideration"); or (iii) cash in an amount equal to the Aggregate Consideration Per Share (as defined in the Merger Agreement) (the "Per Share Cash Consideration").
Footnote F3
Represents shares of Common Stock and shares underlying restricted stock units of Enfusion, which were converted into the right to receive the merger consideration, at the election of the holder of such share of Common Stock.
Footnote F4
As a result of the consummation of the transactions contemplated Merger Agreement, the Reporting Person ceased to be the beneficial owner of any securities of Enfusion. This Form 4 constitutes an exit filing by the Reporting Person.